BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Biomoneta: Transforming Indoor Air Quality Through Microbial Intelligence

16 November 2026 | Features

As concerns around airborne microbial contamination grow across hospitals, laboratories and homes, Biomoneta Research is developing technology that combines microbial air treatment with environmental surveillance. Founded in India in 2014, the biotechnology company brings together microbiology, materials science, electronics and airflow engineering to address indoor microbial risks through a portfolio of air-treatment devices and monitoring solutions.

Biomoneta

Problem

Airborne microorganisms pose a persistent challenge in healthcare facilities, laboratories and indoor environments. Conventional air filtration primarily focuses on removing particulate matter, while institutions also need solutions to address microbial contamination and monitor changes in indoor microbial conditions.

Product

Biomoneta's proprietary **ZeBox** technology uses an electric field to capture airborne microorganisms on an antimicrobial surface, where they are inactivated. Its portfolio includes **Avata Rx** for healthcare environments, **Avata Air** for homes and **qAMI**, a platform that estimates microbial levels and tracks environmental microbial trends.

Proof

In November 2025, Avata Rx received US FDA 510(k) clearance as a Class II medical recirculating air cleaner under K251872. In September 2026, Avata Air entered the consumer market through Panasonic's MirAIe Lifestyle platform. The company has also deployed its technology in healthcare and laboratory environments.

People

Co-founded by **Arindam Ghatak, Dr. Janani Venkatraman and Dr. Santanu Datta**, Biomoneta's leadership combines expertise in infectious-disease research, biotechnology and commercialisation. Its technical capabilities are further supported by **Prof. Sujit Kumar Biswas**, who brings extensive experience in power electronics and engineering.

Purse

In June 2020, Biomoneta announced seed funding led by Japan-based **Beyond Next Ventures**, through the C-CAMP–BNV Innovation Hub, alongside **ArthaVida Ventures** and angel investor **Dr. Aniruddha Malpani**. The company has also received institutional support from DBT-BIRAC, C-CAMP, the Government of Karnataka and the UK-supported GAMRIF programme. It is currently raising US$3 million to support its next phase of growth.

Plan

Biomoneta plans to expand its healthcare and consumer markets, strengthen distribution partnerships and scale manufacturing and customer support. It is also exploring international expansion and technology integration and licensing opportunities with equipment manufacturers, while developing qAMI's environmental surveillance capabilities.

Why it matters

Indoor air quality is an important dimension of infection prevention, particularly in hospitals and laboratories where microbial contamination can have significant consequences. By bringing microbial air treatment and environmental surveillance into one portfolio, Biomoneta is working towards a more comprehensive approach to managing indoor microbial conditions.

FAST FACTS

Particulars	Details
Company	Biomoneta Research Private Limited
Inception	2014
Headquarters	India
Industry	Biotechnology, Air Treatment, Infection Prevention
Co-founders	Arindam Ghatak, Dr. Janani Venkatraman, Dr. Santanu Datta
Key Technology	ZeBox
Key Products	Avata Rx, Avata Air, qAMI
Regulatory Milestone	US FDA 510(k) clearance for Avata Rx, November 2025
Consumer Launch	Avata Air through Panasonic MirAIe Lifestyle, September 2026
Seed Investors	Beyond Next Ventures, ArthaVida Ventures, Dr. Aniruddha Malpani
Funding Support	DBT-BIRAC, C-CAMP, Government of Karnataka, GAMRIF
Current Fundraising	US$3 million
Website	Biomoneta